Contents

Highlights of This Issue  2997

SPECIAL FEATURES

CCR Translations  2999

Serum Cholesterol and mTOR Inhibitors: Surrogate Biomarker or Epiphenomenon?
Daniel C. Cho and Michael B. Atkins
See article p. 3188

CCR New Strategies  3002

New Strategies in Squamous Cell Carcinoma of the Lung: Identification of Tumor Drivers to Personalize Therapy
Kathryn A. Gold, Ignacio I. Wistuba, and Edward S. Kim

CCR Drug Updates  3008

Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis
John Mascarenhas and Ronald Hoffman

Molecular Pathways  3015

Molecular Pathways: Interferon/Stat1 Pathway: Role in the Tumor Resistance to Genotoxic Stress and Aggressive Growth
Nikolai N. Khodarev, Bernard Roizman, and Ralph R. Weichselbaum

Review  3022

The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature
Ronald J. deLeeuw, Sara E. Kost, Juizher A. Kakal, and Brad H. Nelson

HUMAN CANCER BIOLOGY

MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma
John S. Jarhoe, Joshua C. Anderson, Christine W. Duarte, Tapan Mehta, Somaira Nowsheen, Patricia H. Hicks, Alexander C. Whitley, Timothy D. Rohrbach, Raymond O. McCubrey, Sherard Chiu, Tamara M. Burleson, James A. Bonner, G. Yancey Gillespie, Eddy S. Yang, and Christopher D. Willey

Decreased Selenium-Binding Protein 1 Enhances Glutathione Peroxidase 1 Activity and Downregulates HIF-1α to Promote Hepatocellular Carcinoma Invasiveness
Cheng Huang, Guangyu Ding, Chengyu Gu, Jian Zhou, Ming Kuang, Yuan Ji, Yifeng He, Tadashi Kondo, and Jia Fan

Microarray Analysis of Colorectal Cancer Stromal Tissue Reveals Upregulation of Two Oncogenic miRNA Clusters
Naohiro Nishida, Makoto Nagahara, Tetsuya Sato, Koshi Mimori, Tomoya Sudo, Fumiaki Tanaka, Kohei Shibata, Hideshi Ishii, Kenichi Sugihara, Yuichiro Doki, and Masaki Mori

Aberrant L1 Cell Adhesion Molecule Affects Tumor Behavior and Chemosensitivity in Anaplastic Thyroid Carcinoma
Koon Soon Kim, Jeong-Ki Min, Zhe Long Liang, Kyungmin Lee, Jung Uee Lee, Kwang-Hee Bae, Min Hee Lee, Seong Eun Lee, Min Jeong Ryu, Soong Jung Kim, Yong Kyoung Kim, Min Jeong Choi, Young Suk Jo, Jin-Man Kim, and Minho Shong

Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients
Elena Spinelli, Roberto Caporale, Francesca Buchi, Erico Masala, Antonella Gozzini, Alessandro Sanna, Francesca Sassolini, Ana Valencia, Alberto Best, and Valeria Santini
Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor
Harvey Wong, Laurent Vernillet, Amy Peterson, Joseph A. Ware, Lillian Lee, Jean-Francois Martini, Peiwen Yu, Congfen Li, Geoffrey Del Rosario, Edna F. Choo, Klaus P. Hoeflich, Yongchang Shi, Blake T. Aftab, Ron Aoyama, Sanh Tan Lam, Marcia Belvin, and John Prescott

Carbonic Anhydrase IX Promotes Tumor Growth and Necrosis In Vivo and Inhibition Enhances Anti-VEGF Therapy
Alan McIntyre, Shalini Patiar, Simon Wigfield, Ji-liang Li, Ioanna Ledaki, Helen Turley, Russell Leek, Cameron Snell, Kevin Gatter, William S. Sly, Richard D. Vaughan-Jones, Pawel Swietach, and Adrian L. Harris

The Effects of Chemotherapy on Cognitive Function in a Mouse Model: A Prospective Study
Gordon Winocur, Mark Henkelman, J. Martin Wojtowicz, Haibo Zhang, Malcolm A. Binns, and Ian F. Tannock

Dendritic Cell–Activating Vaccine Adjuvants Differ in the Ability to Elicit Antitumor Immunity Due to an Adjuvant-Specific Induction of Immunosuppressive Cells
Yushe Dang, Wolfgang M. Wagner, Ekram Gad, Lauren Rastetter, Carmen M. Berger, Gregory E. Holt, and Mary L. Disis

Mutations in the Ras–Raf Axis Underlie the Prognostic Value of CD133 in Colorectal Cancer
Kristel Kemper, Miranda Versloot, Katherine Cameron, Selcuk Colak, Felipe de Sousa e Melo, Joan H. de Jong, Joanne Bleackley, Louis Versteeg, Rogier Versteeg, Jan Koster, and Jan Paul Medema

MSH3 Protein Expression and Nodal Status in MLH1-Deficient Colorectal Cancers
Luigi Laghi, Paolo Bianchi, Gabriele Delconte, Giuseppe Celesti, Giuseppe Di Caro, Monica Pedroni, Anna Maria Chiaravalli, Barbara Jung, Carlo Capella, Maurizio Ponz de Leon, and Alberto Malesci

SSBP2 Variants Are Associated with Survival in Glioblastoma Patients

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure

Subclinical Peripheral Neuropathy Is a Common Finding in Colorectal Cancer Patients Prior to Chemotherapy
Jessica A. Boyette-Davis, Cathy Eng, Xin S. Wang, Charles S. Cleeland, Gwen Wendelschafer-Crabb, William R. Kennedy, Donald A. Simione, Haijun Zhang, and Patrick M. Dougherty
PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Increase in Cholesterol Predicts Survival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus
Chee Khoon Lee, Ian C. Marschner, R. John Simes, Merryn Voysey, Brian Egleston, Gary Hudes, and Paul de Souza
See commentary p. 2999

ABOUT THE COVER

Aberrant L1 cell adhesion molecule (LICAM) affects tumor behavior and chemosensitivity in anaplastic thyroid carcinoma (ATC). LICAM is highly expressed in ATC cells, but not in nodular hyperplasia or papillary thyroid carcinoma (PTC) cells. LICAM plays an important role in the aggressiveness of ATC by enhancing proliferation, migration, invasion, and chemoresistance. Photomicrograph showing immunohistochemical staining for LICAM in PTC tissue. 200X magnification. For details, see the article by Kim and colleagues on page 3071 of this issue.